The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

Regulatory NewsRegulatory News
This Week at FDA: Pediatric use for Lilly’s COVID mAbs; Will Woodcock stay on?
Posted 03 December 2021 By Michael Mezher, Kari Oakes
Welcome to month two of our weekly digest of regulatory news from the US Food and Drug Administration (FDA) and other corners of the health care product world. This week saw the expansion of Eli Lilly’s emergency use authorization (EUA) ...
TrackersTrackers
COVID-19 vaccine tracker
Posted 03 December 2021 By Jeff Craven
Updated 03 December with new information on vaccines from Pfizer/BioNTech, Moderna, AstraZeneca, Gamaleya Research Institute, Janssen Vaccines, Sinovac, Bharat Biotech, Shifa Pharmed Industrial Group, and the first authorization of the...
Regulatory NewsRegulatory News
FDA expands eSTAR filing to de novo devices, IVDs
Posted 02 December 2021 By Kari Oakes
US medical device and in vitro diagnostic sponsors who are using the Food and Drug Administration’s de novo pathway will be able to use the eSTAR filing format at the beginning of 2022. A pilot program for the eSTAR template that kic...
Regulatory NewsRegulatory News
FDA announces FY 2022 GDUFA science and research priorities
Posted 02 December 2021 By Joanne S. Eglovitch
The US Food and Drug Administration’s (FDA) Office of Generic Drugs (OGD) has announced its science and research priorities for fiscal year (FY) 2022 to spur the development of complex generic drugs.
RoundupsRoundups
Euro Roundup: EMA chief calls for extra staff to handle growing workload
Posted 02 December 2021 By Nick Paul Taylor
The executive director of the European Medicines Agency (EMA) has told politicians her teams need more support to cope with COVID-19 and their soon-to-be-extended mandate.
ReconRecon
Recon: EMA starts rolling review of Valneva’s COVID vaccine; Biden eyes free at-home tests to curb Omicron
Posted 02 December 2021 By Michael Mezher
Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
Regulatory NewsRegulatory News
New reports address generics pricing, innovation in the EU
Posted 01 December 2021 By Kari Oakes
A European generics trade association is calling for relaxation of “extreme cost containment policies” against generic medicines, asserting that such measures are counterproductive and may endanger the supply chain through consolidation ...
Regulatory NewsRegulatory News
EU official says ICH Q6B is outdated and needs revision
Posted 01 December 2021 By Joanne S. Eglovitch
The International Council for Harmonization’s (ICH) Q6B guideline setting acceptance criteria for new biological products needs to be revised to incorporate a more patient-centric approach and to include the science and risk-based concep...
Virtual Programs Virtual Programs
Sponsored Webcast: Best Practices on MDR Transition Under Current Conditions
Wednesday, 15 December 2021 (11:00 - 12:00PM) 1.0 RAC Credits Member: $0 NonMember: $0
As one of the leading Notified Bodies in these transition cases, BSI will share a series of lessons learned from actual case reports of manufacturers moving through the transitioning to applying the EU MDR
Virtual Programs Virtual Programs
Impact of MDR on Drug-Device Combination Products: Notified Body Opinion and CE Mark Applications
Thursday, 16 December 2021 (9:00 - 2:00PM) 6.0 RAC Credits Member: $580 Non-Member: $680
Learn how EU MDR 2017/745 affects integral drug-device combinations and how to develop a complete dossier for Notified Body review.
Virtual Programs Virtual Programs
Sponsored Webcast: Making Sense of FDA's 2021 Real-World Evidence Guidance
Thursday, 09 December 2021 (10:00 - 11:30AM) 1.0 RAC Credits Member: $0 NonMember: $0
Join a discussion on FDA’s RWE guidance landscape, including how new draft guidance fits into the current ecosystem and implications for biopharma organizations as they develop evidence generation strategies.
Virtual Programs Virtual Programs
Rollout IVDR 2022: What can IVD manufacturers learn from the MDR rollout when establishing compliance for their IVD devices by May 2022?
Tuesday, 07 December 2021 (10:00 - 11:30AM) 1.0 RAC Credits Fee: $0
This webcast will cover the potential impact of IVDR implementation in 2022 for new and existing (legacy) devices and considerations learned from the MDR rollout for IVD manufacturers to consider when determining regulatory strategy
Virtual Programs Virtual Programs
Europe Europe
In-Person In-Person
RA Considerations During Clinical Development in the EU
Thursday, 17 February 2022 (9:00 - 4:00PM) 6.0 RAC Credits Members: € 555 Nonmembers: € 650
Learn which aspects to consider when writing a regulatory plan, along with several pathways to speed up development, including PRIME and adaptive pathways.
Virtual Programs Virtual Programs
COVID-19 In Vitro Diagnostics: A Look into FDA’s Regulatory Response
Thursday, 10 February 2022 (1:00 - 2:00PM) 1.0 RAC Credits Member: $0 NonMember: $0
This presentation will discuss the FDA Emergency Use Authorization Guideline and how the guidance has changed over time. It will cover the scientific basics of COVID-19, the biomarkers used to detect it, the types of tes
Virtual Programs Virtual Programs
Biologics CMC: Phase Appropriate Product Development
Tuesday, 14 December 2021 (9:00 - 4:00PM) 12.0 RAC Credits Member: $800 Nonmember: $900
Learn how to handle technical issues affecting biologic product development challenges and expectations in the US, Europe, and other highly regulated regions.
Virtual Programs Virtual Programs
Biologics CMC: Phase Appropriate Product Development
Thursday, 17 March 2022 (9:00 - 4:00PM) 12.0 RAC Credits Member: $825 Nonmember: $970
Learn how to handle technical issues affecting biologic product development challenges and expectations in the US, Europe, and other highly regulated regions.
     
  •  
  • 1
  •  
  • 2
  •  
  • 3
  •  
  • 4
  •  
  • 5
  •  
  •  
On-demand On-demand
Managing Global Regulatory Complexity: Five Strategies to Optimize Regulatory Compliance in New Markets
1.0 RAC Credits
Member: $0.00 Nonmember: $20.00
Join us for a regulatory professional’s presentation on Managing Global Regulatory Complexity: Five Strategies to Optimize Regulatory Compliance in New Markets.
Online Course Online Course
Single Certificate Single Certificate
Regulatory Affairs Certificate Upgrade: Medical Devices
Member: $1225 Nonmember: $1580
If you have already successfully completed a Regulatory Affairs Certificate in Pharmaceuticals, you can complete the two remaining core courses of the Dual Certificate and three additional electives.
Online Course Online Course
Single Certificate Single Certificate
Regulatory Affairs Certificate Upgrade: Pharmaceuticals
Member: $1225.00 Nonmember: $1580
If you have already successfully completed a Regulatory Affairs Certificate in Medical Devices, you can complete the two remaining core courses of the Dual Certificate and three addition electives.
On-demand On-demand
A Risk-Based Approach to Validation for Life Sciences Companies
1.0 RAC Credits
Member: $0.00 Nonmember: $20.00
Learn how a risk-based validation approach can meet compliance requirements and maintain quality while streamlining the validation process.
Books Books
The Medical Device Validation Handbook, Second Edition (Hardcover)
Member: $125.00 Nonmember: $175.00
The handbook covers device validation and revalidation throughout the product lifecycle, from design through postmarket.
On-demand On-demand
21 CFR 820 Quality System Regulation and ISO 13485 Medical Devices
1.5 RAC Credits
Member: $0.00 Nonmember: $35.00
The RAPS Philadelphia Chapter’s webcast covering 21 CFR 820 quality system regulation and ISO 13485 medical devices.
Books Books
The European Medical Device Regulation (2021 Update) (Paperback)
Member: $295.00 Nonmember: $395.00
Your “go-to” EU MDR guide and tool kit intended to be your companion to reference time and time again.
On-demand On-demand
US Regulation of Advertising, Promotion and Labeling for Medical Devices
6.0 RAC Credits
Member: $399.00 Nonmember: $499.00
Through presentations, discussions and case studies, this program will examine current guidelines and expectations for medical devices and how they impact the way you communicate with prospective and end users.

All Results

Virtual Programs Virtual Programs

Sponsored Webcast: Best Practices on MDR Transition Under Current Conditions

Wednesday, 15 December 2021 (11:00 - 12:00PM)
1.0RAC Credits
Member: $0 NonMember: $0
As one of the leading Notified Bodies in these transition cases, BSI will share a series of lessons learned from actual case reports of manufacturers moving through the transitioning to applying the EU MDR